Article Sidebar

pdf
Date Published: 05/01/2026
Abstract Views: 54
Views pdf: 32
DOI: https://doi.org/10.51298/vmj.v557i3.16763
Issue
Vol. 557 No. 3 (2025)
Section
Các bài báo
How to Cite
Nông, T. T. Điểm, Nguyễn, V. L., Trần, T. K. P., & Phạm, Đình P. (2026). EVALUATION OF TREATMENT RESULTS WITH mFOLFOX6 - BEVACIZUMAB REGIMEN IN PATIENTS WITH STAGE IV COLON CANCER. Vietnam Medical Journal, 557(3). https://doi.org/10.51298/vmj.v557i3.16763

EVALUATION OF TREATMENT RESULTS WITH mFOLFOX6 - BEVACIZUMAB REGIMEN IN PATIENTS WITH STAGE IV COLON CANCER

Thị Thuỳ Điểm Nông, Việt Long Nguyễn, Thị Kim Phượng Trần, Đình Phúc Phạm

Main Article Content

Abstract

Objectives: To evaluate the results of mFOLFOX6 – Bevacizumab regimen in colon cancer patients with stage IV colon cancer at 108 Military Central Hospital. Subjects and Methods: This is a retrospective descriptive study of 56 stage IV colon cancer patients, who were treated with mFOLFOX6 – Bevacizumab regimen from January 2020 to January 2024 at 108 Military Central Hospital. Results: Objective response rate was 62,1%, median progression-free survival (PFS) was 12 months, median overall survial (OS) was 23,1 months. Several factors were statistically significantly associated with PFS and OS, including tumor progression, CEA levels, number of metastatic sites and response rate. Conclusion: The mFOLFOX6 – Bevacizumab regimen resulted in high objective response rate, promising PFS, OS. Several factors related to PFS and OS include tumor progression, CEA levels, number of metastatic sites and treatment response level with prognostic significance

Article Details

Keywords

colon cancer metastasis, mFOLFOX6 – Bevacizumab.

References

Trần Kiến Bình, Võ Văn Kha, Lê Thanh Vũ (2023), "Kết quả hoá trị kết hợp với Bevacizumab trong carcinom tuyến đại – trực tràng di căn tại Bệnh viện Ung bướu Cần Thơ năm 2019-2021", Tạp chí Y Dược học Cần Thơ, (40), pp. 143-149.
2. Trịnh Nguyễn Hương Giang, Nghiêm Thị Minh Châu, Nguyễn Xuân Anh, et al. (2024), "Đánh giá kết quả điều trị của phác đồ Bevacizumab – mFOLFOX6 trong điều trị bước 1 bệnh nhân ung thư đại trực tràng giai đoạn IV", Tạp chí Y học Việt Nam, 539 (2), pp. 18-22.
3. Đỗ Huyền Nga (2018), "Đánh giá kết quả hóa trị phác đồ FOLFOX 4 kết hợp Bevacizumab trong ung thư đại - trực tràng di căn", Luận án Tiến sĩ Y học, Đại học Y Hà Nội.
4. Bray F, Laversanne M, Sung H, et al. (2024), "Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 74 (3), pp. 229-263.
5. Hochster HS, Hart LL, Ramanathan RK, et al. (2008), "Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study", J Clin Oncol, 26 (21), pp. 3523-9.
6. Ocvirk J, Brodowicz T, Wrba F, et al. (2010), "Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial", World J Gastroenterol, 16 (25), pp. 3133-43.
7. Prager GW, Braemswig KH, Martel A, et al. (2014), "Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer", Cancer Sci, 105 (8), pp. 996-1001.
8. Rumpold H, Kirchweger P, Niedersüß-Beke D, et al. (2021), "Prognostic value of metastatic pattern in colorectal cancer: a multicenter retrospective analysis in a real-life cohort", Acta Oncologica, 60 (2), pp. 180-186.
9. Rumpold H, Niedersüß-Beke D, Heiler C, et al. (2020), "Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis", BMC Cancer, 20 (1), pp. 1149.
10. Yamazaki K, Nagase M, Tamagawa H, et al. (2016), "Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)", Ann Oncol, 27 (8), pp. 1539-46.